FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127281738> ?p ?o ?g. }

• W2127281738 endingPage "2457" @default.
• W2127281738 startingPage "2452" @default.
• W2127281738 abstract "There is no consensus regarding the optimal second induction course regimen for patients with acute myeloid leukemia (AML) refractory to an initial course of front-line induction. The CAG regimen (cytarabine, aclarubicin and granulocyte colony-stimulating factor) has shown promise for relapsed/refractory AML. We retrospectively compared the efficacy and toxicity of the CAG regimen (n = 44) with a non-CAG regimen (n = 31) in 75 patients with AML refractory to an initial induction chemotherapy. The complete remission (CR) rate was higher for the CAG than the non-CAG regimen (63.5% vs. 38.7%, p = 0.038), and this was more pronounced in the subgroup of patients with a lower white blood cell (WBC) count before first/second induction, better- and intermediate-risk patients, and non-AML-M4/5 (p = 0.019). Although the CAG group demonstrated a higher disease-free survival than the non-CAG group among the intermediate- and poor-risk patients (p = 0.019), no differences in overall survival were observed. The CAG regimen produced hematological and non-hematological side effects similar to those of the non-CAG regimen. The most frequent CAG regimen side effects were infection (45.5%), fever (50%) and elevated transaminase levels (31.8%). No patients died within 4 weeks after initiating the second induction course in the CAG regimen. Thus, CAG represents a highly effective and safe salvage regimen for patients with AML who are refractory to the first induction chemotherapy. This regimen may be of specific benefit for CR in patients with low WBC count, better- and intermediate-risk, and non-M4/5 disease." @default.
• W2127281738 created "2016-06-24" @default.
• W2127281738 creator A5001717980 @default.
• W2127281738 creator A5010680257 @default.
• W2127281738 creator A5013530856 @default.
• W2127281738 creator A5016322565 @default.
• W2127281738 creator A5037029781 @default.
• W2127281738 creator A5052596963 @default.
• W2127281738 creator A5057603195 @default.
• W2127281738 creator A5061407928 @default.
• W2127281738 creator A5088917859 @default.
• W2127281738 date "2013-04-02" @default.
• W2127281738 modified "2023-09-22" @default.
• W2127281738 title "Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy" @default.
• W2127281738 cites W1143126211 @default.
• W2127281738 cites W1602123006 @default.
• W2127281738 cites W1982766090 @default.
• W2127281738 cites W1996264890 @default.
• W2127281738 cites W2002542702 @default.
• W2127281738 cites W2021176309 @default.
• W2127281738 cites W2034506866 @default.
• W2127281738 cites W2042814209 @default.
• W2127281738 cites W2043938406 @default.
• W2127281738 cites W2066151812 @default.
• W2127281738 cites W2069448515 @default.
• W2127281738 cites W2080799966 @default.
• W2127281738 cites W2112998845 @default.
• W2127281738 cites W2116858301 @default.
• W2127281738 cites W2117844516 @default.
• W2127281738 cites W2119626196 @default.
• W2127281738 cites W2123986795 @default.
• W2127281738 cites W2141129374 @default.
• W2127281738 cites W2141696179 @default.
• W2127281738 cites W2142036452 @default.
• W2127281738 cites W2158022600 @default.
• W2127281738 cites W2162177155 @default.
• W2127281738 cites W4254786437 @default.
• W2127281738 doi "https://doi.org/10.3109/10428194.2013.776679" @default.
• W2127281738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23432721" @default.
• W2127281738 hasPublicationYear "2013" @default.
• W2127281738 type Work @default.
• W2127281738 sameAs 2127281738 @default.
• W2127281738 citedByCount "11" @default.
• W2127281738 countsByYear W21272817382014 @default.
• W2127281738 countsByYear W21272817382015 @default.
• W2127281738 countsByYear W21272817382016 @default.
• W2127281738 countsByYear W21272817382017 @default.
• W2127281738 countsByYear W21272817382018 @default.
• W2127281738 countsByYear W21272817382019 @default.
• W2127281738 countsByYear W21272817382020 @default.
• W2127281738 countsByYear W21272817382021 @default.
• W2127281738 countsByYear W21272817382023 @default.
• W2127281738 crossrefType "journal-article" @default.
• W2127281738 hasAuthorship W2127281738A5001717980 @default.
• W2127281738 hasAuthorship W2127281738A5010680257 @default.
• W2127281738 hasAuthorship W2127281738A5013530856 @default.
• W2127281738 hasAuthorship W2127281738A5016322565 @default.
• W2127281738 hasAuthorship W2127281738A5037029781 @default.
• W2127281738 hasAuthorship W2127281738A5052596963 @default.
• W2127281738 hasAuthorship W2127281738A5057603195 @default.
• W2127281738 hasAuthorship W2127281738A5061407928 @default.
• W2127281738 hasAuthorship W2127281738A5088917859 @default.
• W2127281738 hasConcept C126322002 @default.
• W2127281738 hasConcept C141071460 @default.
• W2127281738 hasConcept C142424586 @default.
• W2127281738 hasConcept C143998085 @default.
• W2127281738 hasConcept C2776611710 @default.
• W2127281738 hasConcept C2776694085 @default.
• W2127281738 hasConcept C2777767877 @default.
• W2127281738 hasConcept C2778041864 @default.
• W2127281738 hasConcept C2778336483 @default.
• W2127281738 hasConcept C2778729363 @default.
• W2127281738 hasConcept C2780847677 @default.
• W2127281738 hasConcept C2781413609 @default.
• W2127281738 hasConcept C71924100 @default.
• W2127281738 hasConcept C86803240 @default.
• W2127281738 hasConcept C87355193 @default.
• W2127281738 hasConcept C90924648 @default.
• W2127281738 hasConceptScore W2127281738C126322002 @default.
• W2127281738 hasConceptScore W2127281738C141071460 @default.
• W2127281738 hasConceptScore W2127281738C142424586 @default.
• W2127281738 hasConceptScore W2127281738C143998085 @default.
• W2127281738 hasConceptScore W2127281738C2776611710 @default.
• W2127281738 hasConceptScore W2127281738C2776694085 @default.
• W2127281738 hasConceptScore W2127281738C2777767877 @default.
• W2127281738 hasConceptScore W2127281738C2778041864 @default.
• W2127281738 hasConceptScore W2127281738C2778336483 @default.
• W2127281738 hasConceptScore W2127281738C2778729363 @default.
• W2127281738 hasConceptScore W2127281738C2780847677 @default.
• W2127281738 hasConceptScore W2127281738C2781413609 @default.
• W2127281738 hasConceptScore W2127281738C71924100 @default.
• W2127281738 hasConceptScore W2127281738C86803240 @default.
• W2127281738 hasConceptScore W2127281738C87355193 @default.
• W2127281738 hasConceptScore W2127281738C90924648 @default.
• W2127281738 hasIssue "11" @default.
• W2127281738 hasLocation W21272817381 @default.
• W2127281738 hasLocation W21272817382 @default.
• W2127281738 hasOpenAccess W2127281738 @default.

• next